Zhang G W, Cheng R R, Wang H J, Zhang Y, Li P, Yan X T, Zhang M N, Zhang X J, Yang J P, Ma Z Y
Department of Medical Oncology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450003, China.
The First Department of Respiratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Zhonghua Zhong Liu Za Zhi. 2020 Nov 23;42(11):961-965. doi: 10.3760/cma.j.cn112152-20190130-00059.
To preliminarily explore the treatment effect of nivolumab on Chinese non-small-cell lung cancer (NSCLC) patients with brain metastases, and further enrich the evidences of programmed death-ligand 1 (PD-1) monoclonal antibody in the treatment of NSCLC patients with brain metastases. The clinical and pathological data of 22 NSCLC patients with brain metastases treated with nivolumab were collected. The electronic imaging data were collected to confirm the treatment effect and time point of disease progression, and the survival data of the patients were obtained through follow-up. Twenty-one patients were evaluated for the intracranial treatment effect. The intracerebral objective response rate (IORR) was 28.6%, the intracranial disease control rate (IDCR) was 47.6%. The median intracranial progression-free-survival (iPFS) of all the 22 patients was 5.2 months. Both the 1-year and 2-year survival rates were 56.7%. The treatment effect of PD-1 monoclonal antibody on NSCLC patients with brain metastases is similar as those without brain metastases.
初步探讨纳武利尤单抗治疗中国非小细胞肺癌（NSCLC）脑转移患者的疗效，进一步丰富程序性死亡配体1（PD-1）单克隆抗体治疗NSCLC脑转移患者的证据。收集22例接受纳武利尤单抗治疗的NSCLC脑转移患者的临床和病理资料。收集电子影像资料以确认治疗效果和疾病进展的时间点，并通过随访获得患者的生存数据。对21例患者进行了颅内治疗效果评估。颅内客观缓解率（IORR）为28.6%，颅内疾病控制率（IDCR）为47.6%。22例患者的中位颅内无进展生存期（iPFS）为5.2个月。1年和2年生存率均为56.7%。PD-1单克隆抗体对NSCLC脑转移患者的治疗效果与无脑转移患者相似。
